Galapagos NV - ADR
GLPG
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.11B
Close$
$-2.90
110.4% downside
Current Fair Value
110.4% downsideOvervalued by 110.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.11 Billion |
|---|---|
| Enterprise Value | $2.05 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $4.85 |
| Beta | 0.3 |
| Outstanding Shares | 70,028,000 |
Return
| Return on Equity | 18.34% |
|---|---|
| Return on Assets | 17.69% |
| Return on Invested Capital | 18.04% |
Valuation & Multiples
| P/E Ratio | 2.93 |
|---|---|
| PEG | -2.88 |
| Price to Sales | 2.0 |
| Price to Book Ratio | 0.61 |
| Enterprise Value to Revenue | 2.07 |
| Enterprise Value to EBIT | 3.47 |
| Enterprise Value to Net Income | 3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.97
Average shareholder expectationRevenue Estimate
$7.29 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 4570.30% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | 449,100▼ 2.71% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 48.67%▲ 1.21% |
|---|---|
| Total Invested | $960.34M▲ 2.40% |
| Investors Holding | 79▼ 14.00% |
ESG Score
No data
About Galapagos NV
452 employees
CEO: Onno van de Stolpe Galapagos N.V. is a fully-integrated biopharmaceutical firm dedicated to discovering, developing, and bringing to market innovative therapies for conditions where patient needs are largely unaddressed. The company boasts a robust pipelin...